Loading data for RNXT — first visit, this takes a few seconds.

Alerta

RenovoRx Inc. (RNXT)

NasdaqCM: RNXT · Precio en tiempo real · USD

1.32

+0.01 (0.76%)

Al cierre: Aug 20, 2026, 8:00 PM

1.30

-1.52%

Fuera de horario: 7:30 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

0.76% (1D)

No hay datos disponibles

Precio de compra	0.96
Capitalización de mercado	59.57M
Ingresos (TTM)	1.98M
Beneficio neto (TTM)	-12.29M
	0.99
	-0.31
	n/a
	-8.52
P/B (TTM)	6.63
P/S (TTM)	30.15
Fecha de resultados	Aug 14, 2025

Precio de venta	1.6
Volumen	378,974
Volumen medio (20D)	329,719
Abierto	1.30
Anterior Cerrar	1.31
Rango del día	1.23 - 1.35
Rango de 52 semanas	0.70 - 1.50
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de RNXT

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, Calif...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Aug 26, 2021

Empleados 17

Bolsa de Valores NasdaqCM

Símbolo bursátil RNXT

Sitio web https://renovorx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de RenovoRx fueron 1.12M, un aumento de 2,511.63% en comparación con 43K del año anterior. Las ganancias fueron -11.17M, un aumento de 26.71%.

Estados financieros

Sorpresa de resultados

RenovoRx ha publicado sus resultados trimestrales en May 14, 2026:

Ingresos de $563K falla las estimaciones por $0, con 185.79% Crecimiento interanual.

EPS de -0.08 falla las estimaciones por 0.00, con 0.00% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que RenovoRx Inc. publique sus resultados el Aug 14, 2025, después del cierre del mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Zacks

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 semana hace · Benzinga

EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027

RenovoRx, Inc. (NASDAQ:RNXT) announced Tuesday that it has completed patient enrollment for its Phase 3 TIGeR-PaC study of its targeted drug delivery platform for locally advanced pancreatic cancer (L...

1 semana hace · Zacks

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock...

2 semanas hace · Zacks

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 semanas hace · Zacks

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Página 1 de 2

RenovoRx Inc. (RNXT)